Innovation History
September 2010 -- Stereotaxis announces that the U.S. Patent and Trademark Office granted the Company its 100th patent, a major intellectual property milestone.
September 2010 -- At European Cardiology Society Annual Congress, Dr. Tamas Szili-Torok from the Erasmus Medical Center in Rotterdam presented the first comparative trial in a prospective study of 64 consecutive VT patients, showing 97% acute success in the Stereotaxis VT ablation group versus 81% of the manual ablation group. Patients in the Stereotaxis VT group averaged 50% less x-ray exposure, and after a year, only 14% VT recurrence, versus a 50% recurrence rate among manual ablation patients.
May 2010 -- Stereotaxis introduced Vdrive™, an expansion of its Magnetic Navigation platform that facilitates remote manipulation of diagnostic devices used during electrophysiology procedures.
February 2010 -- Stereotaxis' Magnetic Navigation system featured on NBC's The Today Show.
August 2009 -- Five thousand cases performed with the NAVISTAR® RMT THEMOCOOL® Catheter. February 2009 -- U.S. Food and Drug Administration approved for marketing the NAVISTAR® RMT THERMOCOOL® Catheter, the magnetic irrigated catheter, manufactured by Biosense Webster for the magnetic navigation system.
October 2008 -- Stereotaxis introduces Odyssey™Cinema, the core of the Odyssey™ Enterprise advanced information management platform.
July 2008 -- The pediatric cardiology team at the Heart and Diabetes Center of North Reinland-Westphalia in Bad Oeynhausen, Germany, successfully performed a first-of-its-kind-procedure with the Magnetic Navigation System to treat pulmonary atresia in a 10-year old boy.
May 2008 -- At Heart Rhythm 2008, Dr. Xu Chen of the Rigshospitalet -- Copenhagen University Hospital, reported 100% acute success and 92% chronic success, with zero complications, in pediatric supraventricular tachycardia cases performed with the Magnetic Navigation System.
May 2008 -- First bi-directional live case transmission and training course recently conducted via the Odyssey™ Network, between San Raffaele University Hospital in Milan, Italy and Northeast Georgia Medical Center in Gainesville, Georgia
May 2008 -- Fifteen thousand procedures performed with magnetic navigation system, in all four chambers of the heart and in every type of cardiac patient. Safety record remains exemplary, with less than .1% of reported cardiovascular complications.
February 2008 -- The U.S. Food and Drug Administration approves Stereotaxis' partnered magnetic irrigated catheter for use in mapping and ablation.
October 2007 -- At the recent European Society of Cardiology Congress, Xu Chen, M.D., of the Rigshospitalet at the University of Copenhagen, reports a 93% acute success rate in patients treated for atrial fibrillation with the magnetic navigation system. Dr. Chen presented the data.
September 2007 -- Ten thousand magnetic navigation procedures performed worldwide; peerless safety record established. The incidence of all reported cardiovascular complications associated with the use of magnetic catheters stands at approximately 0.1%.
May 2007 -- Stereotaxis introduced the Odyssey™ system; its partnered magnetic irrigated ablation catheter receives CE approval.
January 2007 -- Drs. Richard Shepard and Kenneth Ellenbogen from the Medical College of Virginia publish detailed approaches to more easily and effectively perform CRT procedures with the magnetic navigation system in the Journal of Cardiac Electrophysiology.
January 2006 -- U.S. Food and Drug Administration approves Biosense Webster's NaviStar® RMT Steerable Tip Diagnostic/Ablation Catheter, the first ablation catheters cleared for use with the Magnetic Navigation System and the CartoTM RMT Electroanatomic Mapping System.
December 2005 -- U.S. Food and Drug Administration approves Biosense Webster's Celsius® RMT Steerable Tip Diagnostic/Ablation Catheter, the first ablation catheters cleared for use with the Magnetic Navigation System
November 2005 -- The first automated mapping of a patient's right atrial heart chamber in conjunction with the treatment of a difficult to ablate tachyarrhythmia successfully completed with the Magnetic Navigation System.
October 2005 -- U.S. Food and Drug Administration gives Biosense Webster clearance for its Carto™ RMT Navigation System and NaviStar® RMT Catheter for use with the magnetic navigation system.
August 2004 -- Stereotaxis offers its first common shares for sale on the NASDAQ stock market, at $8.00 per share.
September 2002 -- Stereotaxis partners with Siemens by integrating Siemen's digital fluoroscopy with its magnetic navigation system, to improve catheter imaging and positioning. A partnership with Siemens remains in place.
January 2001 -- Physicians at Barnes-Jewish Hospital first to use Magnetic Navigation System to steer a catheter within the beating heart of a patient, to discover the source of cardiac arrhythmias, or irregular heartbeats.
December 1998 -- Stereotaxis' Magnetic Navigation System used on first patient, to biopsy a brain tumor, by physicians at Barnes-Jewish Hospital in St. Louis.
